Biotech entity
All 1 tracked stories fall under one category: pharma. BMO Capital Markets is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Biotech story that mention Konstantinos Xynos, all published on August 16, 2026.
Last mentioned: Aug 16, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. BMO Capital Markets is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Biotech story that mention Konstantinos Xynos, all published on August 16, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 7 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Konstantinos Xynos. Shared-story counts are live from our verified record — not editorial picks.
Earnings release
Replimune Group reported ($0.72) EPS, missing the ($0.69) Zacks consensus by $0.03. Stock opened at $14.97, down $0.22.
Insider sales
CEO Sushil Patel sold 39,341 shares at $12.97 and insider Konstantinos Xynos sold 11,447 shares at $12.97, both to cover tax withholding obligations.
Wedbush upgrade
Wedbush upgraded Replimune Group from neutral to outperform and set a $12.00 price target.
Leerink upgrade
Leerink Partners upgraded Replimune Group from market perform to outperform and raised its price target from $11.00 to $17.00.
BMO upgrade
BMO Capital Markets raised Replimune Group from underperform to outperform with a $16.00 price target.
Wall Street Zen upgrade
Wall Street Zen upgraded Replimune Group from strong sell to sell.
Replimune reported ($0.72) EPS, missing by $0.03, but for biotech investors the quarter is a side note to pipeline catalysts and analyst upgrades. Insider sales were tax-related, and recent price targets of $16 to $17 suggest confidence in the oncolytic immunotherapy platform.
Source: tickerreport.com · themarketsdaily.com
Konstantinos Xynos is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
